Nitric oxide produces its anti-aggregatory action by increasing the levels of
## **Core Concept**
Nitric oxide (NO) plays a significant role in vascular tone regulation and platelet aggregation. Its anti-aggregatory effect is primarily mediated through a specific signaling pathway involving cyclic nucleotides.
## **Why the Correct Answer is Right**
The correct answer, , is correct because nitric oxide exerts its anti-aggregatory action by stimulating **guanylyl cyclase** in platelets. This enzyme catalyzes the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP). Increased levels of **cGMP** activate **protein kinase G**, which in turn inhibits platelet activation and aggregation. This pathway is crucial for the regulation of vascular tone and prevention of thrombosis.
## **Why Each Wrong Option is Incorrect**
- **Option A:** - Incorrect because while cAMP is indeed a cyclic nucleotide involved in inhibiting platelet aggregation, its pathway is distinct from that of NO. cAMP works through **protein kinase A** and is primarily increased by **prostacyclin** and **beta-adrenergic agonists**.
- **Option B:** - Incorrect because phospholipase C is involved in the signaling pathway of various platelet agonists, leading to an increase in intracellular calcium and activation of protein kinase C, which promotes platelet aggregation.
- **Option D:** - Incorrect because phosphodiesterase inhibitors, not the enzyme itself, increase levels of cyclic nucleotides (cGMP and/or cAMP) by preventing their degradation. This action can indirectly support the anti-aggregatory effects of NO.
## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that **nitroglycerin** and other **nitrates** exert some of their effects through the release of nitric oxide, leading to vasodilation and potentially influencing platelet aggregation. This mechanism is relevant in the management of **angina pectoris** and acute coronary syndromes.
## **Correct Answer:** .